FDA Approves Stiolto Respimat Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Press/Media: Press / Media

PeriodOct 11 2018

Media coverage

1

Media coverage

  • TitleFDA Approves Stiolto Respimat Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
    Media name/outletPharmacy Choice
    CountryUnited States
    Date10/11/18
    PersonsAntonio R Anzueto